Skip to main content
Clinical Trials/NCT06463288
NCT06463288CompletedNot Applicable

Comparison of Jacobson Relaxation Technique and Pranayama Technique in Patients With COPD

Riphah International University2 sites in 1 country30 target enrollmentStarted: July 20, 2023Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
30
Locations
2
Primary Endpoint
Dyspnea Severity (Borg Scale)

Study Overview

Brief Summary

Comparison of Jacobson Relaxation Technique and Pranayama Technique in patients with COPD

Detailed Description

Chronic obstructive pulmonary disease is a chronic inflammatory lung disease that cause obstructed airflow from the lungs. Symptoms include Breathing difficulty. cough, mucus production and wheezing. Its typically caused by long term exposure to irritating gasses or particulate matter, most often from cigarette smoker. in this study we compare the effect of Jacobson relaxation technique and Pranayama technique on the SOB, Cough, sputum and quality of life in COPD patients.

Data were collected from Gulab Devi Chest Hospital, General Hospital, Jinnah Hospital and Mayo Hospital Lahore. Data were collected by the lottery method. Borg dyspnea scale, Spirometry, CASA-Q and Quality of life questionnaire were used before and after the intervention. Treatment was continuous 4 weeks, 3 times in a week for 15 mint. Assessment was done through the tool before and after the treatment.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Single (Participant)

Masking Description

Single

Eligibility Criteria

Ages
40 Years to 70 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • • Patients of Age between 40 and
  • Both Genders (Male, Female) were included.
  • Stage 2 patient with COPD with Dyspnea FEV1 <70% and Maximal Expiratory Pressure = 50% (Gold Criteria) were included.
  • Cognitive Stable patients were included.
  • Those Patients were included who were clinically stable without exacerbations in the past 01 month.

Exclusion Criteria

  • • Common Cough
  • Upper respiratory tract inflammation
  • Patients who have other co-morbid diseases which prevents them from exercise training, for example, disability due to neurological, orthopedic and acute cardiac causes
  • Patients who were mentally and physically and sick to join at the hospital or research site for training
  • Patients who were already participated or completed or in a P.R program in the past one year.

Outcomes

Primary Outcomes

Dyspnea Severity (Borg Scale)

Time Frame: 4 weeks

The Borg scale measures the severity of dyspnea (shortness of breath). Scale Details: Full Title: Borg Rating of Perceived Exertion (RPE) ScaleFull Title: Borg Rating of Perceived Exertion (RPE) Scale Minimum Value: 0 (No breathlessness at all) Maximum Value: 10 (Maximal breathlessness) Interpretation: Higher scores indicate worse outcomes, meaning greater severity of dyspnea.

Cough and Sputum Analysis (CASA-Q)

Time Frame: 4 Weeks

The CASA-Q (Cough and Sputum Assessment Questionnaire) evaluates the severity and impact of cough and sputum production. Scale Details: Full Title: Cough and Sputum Assessment Questionnaire (CASA-Q) Minimum Value: 0 (No symptoms) Maximum Value: 100 (Severe symptoms) Interpretation: Higher scores indicate worse outcomes, meaning more severe symptoms of cough and sputum.

Spirometry (FEV1 and FVC)

Time Frame: 4 Weeks

Spirometry will be used to measure lung function, specifically Forced Expiratory Volume in 1 second (FEV1) and Forced Vital Capacity (FVC). Scale Details: Full Title: Spirometry (FEV1 and FVC) Minimum Value: Variable (dependent on patient's lung function) Maximum Value: Variable (dependent on patient's lung function) Interpretation: Higher values typically indicate better lung function.

Secondary Outcomes

  • Quality of Life (SF-36 Questionnaire)(4 Weeks)
  • Patient Satisfaction (Patient Satisfaction Questionnaire)(4 Weeks)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (2)

Loading locations...

Similar Trials